On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding.
The second quarter saw significant enforcement and dealmaking in the life sciences space. The Federal Trade Commission (FTC) announced its attempt to block Amgen/Horizon, the first such.
The lawsuit was the latest move by the Biden Administration to tackle the high price of prescription drugs. Notably, this is the first FTC pharmaceutical merger challenge in over a decade.
Although the second quarter did not feature any life sciences enforcement action by the FTC, there was plenty of news in and around the space. The FTC held a detailed "virtual workshop" as part of its pharmaceutical.